Icagen, Inc. Successfully Completes Phase I Multiple Ascending Dose Clinical Trial of Senicapoc
RESEARCH TRIANGLE PARK, N.C., July 9, 2008 (PRIME NEWSWIRE) -- Icagen, Inc. (Nasdaq:ICGN) today reported that the Company successfully completed the Phase I multiple ascending dose clinical trial of senicapoc, a novel orally available small molecule inhibitor of the KCa3.1 potassium ion channel, that is being developed for the treatment of asthma. Study results showed that senicapoc was well tolerated at all doses tested and in preliminary analyses exhibited predictable and dose proportional pharmacokinetics consistent with once-daily dosing. There were no serious adverse events and no dropouts from the study. Additionally, there were no dose-limiting toxicities in any subject. The Company expects to initiate a Phase II proof-of-concept clinical trial in asthma during the second half of 2008.